As a key regulator of metabolism and inflammation, the orphan nuclear hormone receptor, Liver Receptor Homolog-1 (LRH-1), has potential as a therapeutic target for diabetes, nonalcoholic fatty liver disease, and inflammatory bowel diseases. Discovery of LRH-1 modulators has been difficult, in part due to the tendency for synthetic compounds to bind unpredictably within the lipophilic binding pocket. Using a structure-guided approach, we exploited a newly-discovered polar interaction to lock agonists in a consistent orientation. This enabled the discovery of the first low nanomolar LRH-1 agonist, one hundred times more potent than the best previous modulator. We elucidate a novel mechanism of action that relies upon specific polar interactions deep in the LRH-1 binding pocket. In an organoid model of inflammatory bowel disease, the new agonist increases expression of LRH-1-conrolled steroidogenic genes and promotes anti-inflammatory gene expression changes. These studies constitute major progress in developing LRH-1 modulators with potential clinical utility.
INTRODUCTION
Liver Receptor Homolog-1 (LRH-1; NR5A2) is a nuclear hormone receptor (NR) that is highly expressed in the liver and tissues of endodermal origin. It is indispensable during embryonic development, where it plays a role in maintenance of pluripotency 1 , as well as in the development of the liver and pancreas 2 . In adults, LRH-1 controls diverse transcriptional programs in different tissues related to metabolism, inflammation, and cellular proliferation. Targeted metabolic pathways include bile acid biosynthesis 3 , reverse cholesterol transport [4] [5] , de novo lipogenesis [6] [7] , and glucose phosphorylation and transport [8] [9] . The ability to modulate lipid and glucose metabolism suggests therapeutic potential for LRH-1 agonists in metabolic diseases such as nonalcoholic fatty liver disease, type II diabetes, and cardiovascular disease. Indeed, the phospholipid LRH-1 agonist dilauroylphosphatidylcholine (DLPC; PC 12:0/12:0) improves glucose tolerance, insulin sensitivity, and triglyceride levels in obese mice 6 . These anti-diabetic effects occur in an LRH-1-dependent manner and have been primarily attributed to a reduction of de novo lipogenesis 6 . In addition, targeting LRH-1 in the gut has therapeutic potential for inflammatory bowel disease, where LRH-1 overexpression ameliorates disease-associated inflammation and cell death 10 .
While small molecule LRH-1 modulators are highly sought, the large and lipophilic LRH-1 binding pocket has been extremely challenging to target. A promising class of agonists developed by Whitby and colleagues features a bicyclic hexahydropentalene core scaffold [11] [12] . The beststudied of this class, named RJW100, was discovered as a part of an extensive synthetic effort to improve acid stability and efficacy of a related compound, GSK8470 12 ( Figure 1A ). We recently determined the crystal structure of LRH-1 bound to RJW100 and made a surprising discovery: it exhibits a completely different binding mode than GSK8470, such that the bicyclic cores of the two agonists are perpendicular to each other ( Figure 1A ) 13 . As a result, the two compounds use different mechanisms to activate LRH-1 but exhibit similar activation profiles in luciferase reporter assays 13 . A tendency for ligands in this class to bind unpredictably in the hydrophobic pocket has likely been a confounding factor in agonist design; however, insights from the LRH-1-RJW100 structure have provided new strategies to improve activity.
In the LRH-1-RJW100 crystal structure, the ligand hydroxyl group contacts a network of water molecules deep in the ligand binding pocket ( Figure 1B ). This water network coordinates a small group of polar residues (e.g. Thr352, His390, and Arg393) in an otherwise predominantly hydrophobic pocket. The endo RJW100 diastereomer adopts a nearly identical pose and makes the same water-mediated contact with Thr352, supporting the idea that this interaction is a primary driver of ligand orientation 13 . Using both a RJW100 analog lacking a hydroxyl group and a LRH-1 Thr352Val mutation, we demonstrated that this interaction is required for RJW100-mediated activation of LRH-1 13 . As the basis for the current studies, we hypothesized that strengthening this and other polar interactions in the vicinity could anchor ligand conformation, enabling more predictable targeting of desired parts of the pocket. We designed, synthesized, and evaluated novel compounds around the hexahydropentalene scaffold with the primary aim of strengthening polar contacts in the deep part of the binding pocket (the deep part of the pocket is hereafter abbreviated "DPP"). This systematic, structure-guided approach enabled the discovery of an agonist more potent than RJW100 by two orders of magnitude. We present three crystal structures of LRH-1 bound to novel agonists, which depict the modified polar groups projecting into the DPP. The best new agonist modulates expression of LRH-1-controlled, anti-inflammatory genes in intestinal organoids, suggesting therapeutic potential for treating inflammatory bowel diseases. This breakthrough in LRH-1 agonist development is a crucial step in developing potential new treatments for metabolic and inflammatory diseases.
RESULTS
Locking the agonist in place with polar interactions. Our structural studies have revealed that highly similar LRH-1 synthetic agonists can bind unpredictably within the hydrophobic binding pocket, which has presented a challenge for improving agonist design in a rational manner 13 . We reasoned that strengthening contacts within the DPP may anchor synthetic compounds in a consistent orientation and improve potency. To evaluate this hypothesis, we synthesized RJW100 analogs with bulkier polar groups in place of the RJW100 hydroxyl (R 1 ), aiming to displace bridging waters and to generate direct interactions with Thr352 or other nearby polar residues ( Figure 1B ). In parallel, we synthesized compounds designed to interact with other sites in the DPP by (1) modifying the external styrene (R 2 ) to promote interactions with helix 3 or to fill a hydrophobic pocket in the vicinity or (2) incorporating hydrogen bond donors at the meta position of the internal styrene (R 3 ) to promote hydrogen bonding with His390 (also via water displacement) ( Figure 1B Figure 2A ). R 1 was most conveniently varied through modification of the RJW100 alcohol to yield derivatives 1-8, which were synthesized separately as both the endo (N) or exo (X) diastereomers ( Figure 2B ). Oxygen-linked analogs 3 and 5 were formed directly from the to RJW100 (RE). RE was calculated as described in the methods section. RJW100 RE = 1.0 and EC50 = 1.5 +/-0.4 µM. The abbreviation "i.a." refers to inactive compounds for which EC50 values could not be calculated.
diastereomerically-appropriate parent alcohol. Nitrogen-linked analogs 1, 2, 4, 6, and 8 were prepared through alcohol activation (mesylate S4) and substitution (azide S2, nitrile S3) ( Figure   2B and online supplementary materials). Alteration of R 2 was accomplished by introducing phenylacetylene derivatives as the alkyne in the cyclization step (Figure 2A ), generating 9-15
( Figure 2B ). R 3 variants 16-23 were prepared using functionalized enyne starting materials.
Detailed chemical syntheses of all intermediates and tested compounds are provided in the online supplementary materials.
Discovery of the first low nanomolar LRH-1 agonist. We evaluated the new compounds using differential scanning fluorimetry (DSF), since entropic gain from displacement of buried water molecules or favorable energetics from bond formation would result in global stabilization of the LRH-1-agonist complex. DSF assays were paired with cellular luciferase reporter assays to determine effects on LRH-1 transcriptional activity. Luciferase data are summarized in Figure 2C and dose-response curves are shown in Figure S1 .
As previously observed 13, 15 , RJW100 stabilizes the LRH-1 ligand binding domain (LBD) by around 3 ºC relative to a PL ligand in DSF assays ( Figure 3A ). While the R 2 -and R
3
-modified compounds (9-23) destabilize the receptor relative to RJW100 ( Figure 3A ) and tend to be poor activators ( Figure 2C , S1), certain R 1 modifications are highly stabilizing, with Tm values 3-8 °C higher than RJW100 ( Figure 3A and online supplementary material). There is a striking correlation between potency in luciferase reporter assays and LRH-1 stabilization by DSF for the R Figure 3B ). This correlation provides a direct link between cellular activity and receptor stabilization and suggests that improved potency is due to specific polar interactions mediated by the R 1 group. Colored bars represent EC50s relative to RJW100 as indicated in the legend. Each bar represents three experiments conducted in triplicate. *, p< 0.05 for Tm decrease versus RJW100. #, p< 0.05 Tm increase versus RJW100.
Significance was assessed by one-way ANOVA followed by Dunnett's multiple comparison's test. Dotted line indicates the Tm change induced by RJW100 relative to the phospholipid agonist, DLPC. B. Scatter plot showing the correlation between Tm. shift in DSF assay (x-axis) and EC50 from luciferase reporter assays (y-axis) for the R 1 -modified compounds. Data were analyzed by linear regression (curved lines are the 95% confidence interval. C.
Scatter plot comparing potency (EC50) and efficacy relative to RJW100 (relative efficacy, RE) for all compounds for which EC50 values could be calculated. Dots are color-coded by site of modification (as indicated in Figure 2 ). The black dot is RJW100. The EC50 values and efficacies of compounds 2N, 5N, and 6N are indicated. Relative efficacy was calculated as described in the methods section. D. Dose response curves comparing 6N and RJW100 in luciferase reporter assays. Each point represents the mean ± SEM for three experiments conducted in triplicate.
The R 1 modifications are diverse, ranging from small to large polar groups, including hydrogen bond donors and acceptors and endo and exo diastereomers ( Figure 2B ). Both size and stereochemistry of the R 1 group are important for activity. Mid-sized polar groups, mainly tetrahedral in geometry, tend to increase potency relative to RJW100 ( Figure 2C ). The close relationship between R 1 size, agonist potency, and LRH-1 stabilization is evident looking at DSF results, where a strong peak in stabilization occurs for compounds 5 -6 and 8N ( Figure 3A ).
Another strong trend among the data is that endo diastereomers are better activators (and more stabilizing) than the corresponding exo diastereomers (as seen for the triazoles 7, sulfamides 6, and acetamides 2, Figure 2-3 ). While the compounds display a wide range of potencies and efficacies, the endo sulfamide (6N) stands out as being the most potent ( Figure 3C ). With an EC50 of 15.7 ± 0.8 nM, 6N is two orders of magnitude more potent than RJW100 ( Figure 3D ). This is the first discovery of a low-nanomolar LRH-1 modulator, representing a leap forward in developing agonists for this challenging target.
DPP contacts drive LRH-1 activation by 6N. The improved potency of 6N is particularly striking considering that a very similar, highly stabilizing compound (5N) is not much more potent or effective for transcriptional activation than RJW100 ( Figure 3C ). The dramatic increase in potency for 6N relative to 5N is driven by replacement of oxygen with nitrogen in the R 1 linker, as this is the only difference between the two compounds. Remarkably, this effect appears to be generalizable: a nitrogen-containing linker improves potency relative to an oxygen linker for several sets of compounds that differ only at this site ( Figure 4A ). The NH linker also contributes to selectivity for LRH-1 over its closest homolog, Steroidogenic Factor-1 (SF-1). Compound 6N is a weaker activator of SF-1 than LRH-1, and 2N (the endo acetamide) displays no activity against SF-1 while strongly activating LRH-1 ( Figure 4C ). In contrast, 5N and RJW100 equally activate both receptors ( Figure 4C ). To investigate the role of the R 1 linker in agonist activity and to gain insights into mechanisms underlying the potency of 6N, we determined the X-ray crystal structure of 6N bound to the LRH-1 LBD at a resolution of 2.23 Å ( Figure 5A , Table S1 ). For comparison and to delineate the function of the NH-containing linker, we also determined structures of LRH-1 bound to 2N (with an NH-linker, 2.2 Å) and 5N (with an oxygen linker, 2.0 Å) ( Table S1 ). The complexes were crystallized with a fragment of the coactivator protein, Transcriptional
Intermediary Factor 2 (Tif2), which is bound at the AF-2 activation function surface (AFS) at the interface between helices 3, 4, and the activation function helix (AF-H, Figure 5A ). Overall protein conformation does not differ greatly and is similar to the LRH-1-RJW100 structure (root mean square deviations are within 0.2 Å). The ligands are well-defined by the electron density, with the exception of the alkyl "tails" ( Figure 5B ). Disorder in the tail is also seen in the endo RJW100 structure 12 and may be a general feature of endo agonists with this scaffold.
One of the main goals for these studies was to develop ligands that bind with consistent positions of the bicyclic cores. These structures demonstrate that this strategy was successful.
Superposition of RJW100, 2N 5N, and 6N from the crystal structures shows nearly identical conformation of the agonists' cores and phenyl groups, with slight variation in the positions of the R 1 headgroups ( Figure 5C ). All three headgroups protrude into the DPP, filling space typically occupied by one or more water molecules and making several polar contacts ( Figure 5D ).
While the binding modes of the three agonists are similar, mutagenesis studies show that they activate LRH-1 through different mechanisms ( Figure 5E ). The first major difference is with the Thr352 interaction. Both 5N and 6N directly interact with Thr352, but the differential impact of a Thr352Val mutation shows that this interaction only contributes to agonist-mediated LRH-1 activity in the case of 6N ( Figure 5E ). Compound 2N is not well-positioned to interact with the water coordinating Thr352 due to the planar geometry of the R 1 acetamide group, and the Thr352Val mutation has no effect on LRH-1 activity ( Figure 5E ). The agonists also demonstrate a differential reliance on the interaction with M345: 5N is unable to activate a Met345L LRH-1 mutant, but 6N and 2N activate it significantly above basal levels ( Figure 5E ).
We were particularly interested in how interactions made by the NH linker contribute to agonist activity. All three agonists are positioned to make water-mediated hydrogen bonds with LRH-1 residue His390 via the R 1 linkers ( Figure 5D ). In the case of 6N, we were unable to model the bridging water molecule seen in the other two structures (and in other published LRH-1 LBD structures 13, [15] [16] [17] [18] [19] ) due to weak electron density. The weak density for the water molecule is likely a consequence of poor crystallographic order, since very few waters could be modeled in this structure (24 total, unusual for a 2.2 Å structure). However, luciferase reporter assays with LRH-1 mutants indicate that 6N interacts with His390 and that the interaction is critical for transcriptional activity ( Figure 5E ). Compound 2N is also unable to activate the LRH-1 His390Ala mutant, supporting the idea that a productive water-mediated interaction with His390 is made by the NH-linker, ( Figure 5E ). Compound 5N, with an oxygen linker, interacts with His390 with both the linker and sulfonyl oxygens ( Figure 5D ). However, 5N does not utilize the His390 interaction for activation, since mutating His390 to alanine has no effect on its ability to activate LRH-1 ( Figure 5E ). Therefore, while 5N and 6N make very similar contacts, the presence of a hydrogen bond donor in the R 1 linker is uniquely able to drive activation of LRH-1 via His390.
This provides a potential mechanism through which a nitrogen linker increases agonist potency.
Compound 6N stabilizes the AFS, strengthens allosteric signaling, and promotes coactivator recruitment. To investigate how 6N alters LRH-1 dynamics to drive receptor activation, we determined its effects of LRH-1 conformation in solution using hydrogen-deuterium exchange (HDX) mass spectrometry. The most significant changes occur at sites involved in ligand-driven recruitment of coregulators: (1) the activation function surface (AFS) and (2) the helix 6/ β-sheet area (AF-B) involved in allosteric signaling to the AFS [17] [18] . Relative to RJW100, 6N destabilizes N-terminal portion of helix 7 and stabilizes the loop between helices 6 and 7 ( Figure 6A ).
Rigidification of the loop between these helices may induce pressure to unwind helix 7, which could explain this pattern of motion. In addition to these changes near AF-B, 6N strongly stabilizes a portion of helix 4 near the AFS ( Figure 6A ). Compound 5N stabilizes the same region of helix 4, but it also destabilizes helix 12 ( Figure 6B ).
Since 6N alters LRH-1 conformation at AF-B and the AFS, we hypothesized that it increases communication between these two sites. To quantify the predicted strength of agonistdriven communication between AF-B and the AFS, we conducted 1 µs molecular dynamics simulations (MDS) using the crystal structures as starting models. Correlated motions of residues within a protein facilitate allosteric coupling between distant sites [20] [21] [22] . Communication paths can traverse thousands of possible routes through the receptor, and the chains of residues with the strongest patterns of correlated motion-the optimal path and a subset of suboptimal pathsare thought to convey the most information [23] [24] . We therefore constructed dynamical networks of LRH-1-agonist complexes, using calculated covariance to weight the strength of communication between pairs of residues. The resulting covariance matrices were used to identify the strongest suboptimal paths facilitating communication between AF-B and Tif2 coactivator (bound at the AFS). The number of strong paths markedly increases when 2N, 5N, or 6N are bound compared to RJW100, with 6N exhibiting the strongest communication between these sites ( Figure   6C ). There are also significant differences in the directionality of the paths promoted by each agonist. Although all paths traverse helix 5, indicating that correlated motion is induced in this region, compounds 2N, 5N, and 6N also induce strong communication along helix 3. Compound 6N also induces highly interconnected communication within the AFS and the Tif2 coactivator, including significant involvement of the AF-H. This important helix in the AFS is notably excluded from the paths when the other agonists are bound ( Figure 6C ).
The stabilization of the AFS by 6N is associated with enhanced coactivator recruitment.
In a fluorescence-polarization based coregulator binding assay, RJW100, 5N, and 6N dosedependently recruit fluorescein-labeled Tif2 peptide to LRH-1 and exhibit similar EC50s (50% of maximum Tif2 binding occurs with ~600-700 nM agonist, Figure 6D ). Each curve reaches a well-defined plateau that indicates the maximum response with saturating concentrations of agonist; however, curve maxima are lower for RJW100 and 5N than 6N by 50-60%, which is characteristic of partial agonists. Although the endogenous ligand has not been identified for comparison, 6N behaves more like a full agonist than 5N or RJW100 in this assay. Therefore, we have elucidated a novel mechanism of action utilized by 6N, whereby specific interactions by the sulfamide and R 1 linker promote allosteric signaling to the AFS, stabilizing the site of coactivator interaction and increasing Tif2 association.
Compound 6N promotes expression of intestinal epithelial steroidogenic genes in humanized LRH-1 mouse enteroids. The discovery of the first highly potent LRH-1 agonist provides the opportunity to elucidate ligand-regulated transcriptional pathways controlled by this receptor.
LRH-1 controls local steroid hormone production in the gut epithelium [25] [26] , and overexpression of LRH-1 reduces inflammatory damage in immunologic mouse models of enterocolitis 10 . These findings suggest therapeutic potential for LRH-1 agonists in inflammatory bowel diseases (IBD).
The recent development of methods to culture organoids of intestinal crypts (enteroids, Figure 7A) has provided an excellent research tool for drug discovery for IBD 27 . When stimulated with inflammatory cytokines, enteroids mimic features of gut epithelia in IBD 10, 27 . To investigate anti- Figure 7C ).
There was a concomitant increase in expression of the anti-inflammatory cytokine IL-10 and a decrease in expression of the inflammatory cytokines IL-1b, and TNF-a ( Figure 7D-E) . These data suggest a role for 6N in reducing inflammation in the gut via upregulation of steroidogenesis.
Although the involvement of LRH-1 in IBD is clear from gain-and loss-of function studies 10 , the finding that epithelial steroidogenesis can be stimulated by an agonist demonstrates the tremendous potential for LRH-1 as a drug target for this disease. 
DISCUSSION AND CONCLUSION
While the therapeutic potential of LRH-1 is widely recognized, this receptor has been difficult to target with synthetic modulators. Agonists with the hexahydropentalene scaffold [11] [12] (such as RJW100) are promising and have been used in several studies to probe LRH-1 biology [28] [29] [30] [31] [32] . However, we have shown that small modifications to this scaffold can greatly affect binding mode 13 . By exploiting a novel polar interaction in the LRH-1 DPP, we have overcome this challenge and have made substantial progress in agonist development. Systematic variation of three sites on the RJW100 scaffold has revealed a robust structure-activity relationship. The modifications to the styrene sites that we examined (R 2 and R 3 ) do not significantly improve performance and often ablate activity; however, modifications at R 1 increase potency in transactivation assays ( Figure 2C , S1). The increased potency is associated with global receptor stabilization by DSF promoted by tetrahedral, polar R 1 substituents with endo stereochemistry (Figure 3 ). In addition, the composition of the R 1 group, particularly the linker, is critical for activity. This is exemplified through the comparison of 5N and 6N, which differ only at the R 1 linker. Compound 6N utilizes interactions with both Thr352 and His390 to activate LRH-1, the latter of which is likely mediated by the linker nitrogen ( Figure 5D ). This novel binding mode leads to a distinct mechanism of action for 6N compared to similar, less potent compounds, inducing conformational changes at AF-B, stabilization of the AFS, and increasing coactivator association ( Figure 6 ). Results from MDS support the idea that 6N promotes very strong allostery to the AFS, evidenced in the strong communication between the AF-B and the AFS predicted to occur when 6N is bound compared to less potent agonists ( Figure 6 ).
With three separate crystal structures, we demonstrated that polar modifications at the RJW100 R 1 group do not cause major repositioning of the scaffold ( Figure 5 ), supporting our hypothesis that this polar group acts as an important anchor point. This finding was not only key to the success of the current study, but it will also greatly benefit future work. The ability to anchor the scaffold consistently provides an opportunity to tune for additional desired effects, such as solubility or selectivity. Moreover, the trajectory of the alkyl "tails" of these molecules is amenable for introduction of modifications that could engage residues near the mouth of the pocket in a PL-like manner 17, 19 . Initial studies in this vein have been fruitful, leading to the discovery of highly active compounds 33 . Finally, the establishment of a predictable binding mode may open avenues for antagonist design; for example, by modifying the scaffold to promote displacement of the AF-H and recruitment of corepressors. This approach has been successful for other nuclear receptors [34] [35] and could generate LRH-1 antagonists useful as therapeutics for certain cancers in which LRH-1 is aberrantly active [36] [37] [38] [39] [40] [41] [42] . This is an active area of research in our laboratory.
In conclusion, a systematic, structure-guided approach has resulted in the discovery of the first low nanomolar LRH-1 agonist and elucidated a novel mechanism of action. This agonist has great potential as a tool to uncover novel aspects of LRH-1 biology and as a therapeutic for IBD and obesity-associated metabolic diseases. Equally important, the discovery of elements that stabilize the orientation of the hexahydropentalene scaffold and drive activation of LRH-1 is invaluable for understanding ligand-regulation of this receptor and for future modulator design.
EXPERIMENTAL SECTION.
General Chemical Methods. All reactions were carried out in oven-dried glassware, equipped with a stir bar and under a nitrogen atmosphere with dry solvents under anhydrous conditions, unless otherwise noted. Solvents used in anhydrous reactions were purified by passing over activated alumina and storing under argon. Yields refer to chromatographically and spectroscopically ( 1 H NMR) homogenous materials, unless otherwise stated. Reagents were purchased at the highest commercial quality and used without further purification, unless otherwise stated. n-Butyllithium (n-BuLi) was used as a 1.6 M or a 2.5 M solution in hexanes (Aldrich), was stored at 4°C and titrated prior to use. Organic solutions were concentrated under reduced pressure on a rotary evaporator using a water bath. Chromatographic purification of products was accomplished using forced-flow chromatography on 230-400 mesh silica gel. Thin-layer chromatography (TLC) was performed on 250μm SiliCycle silica gel F-254 plates. Visualization of the developed chromatogram was performed by fluorescence quenching or by staining using KMnO4, p-anisaldehyde, or ninhydrin stains. Resolution mass spectra (HRMS) were obtained from the Emory University Mass Spectral facility.
Gas Chromatography Mass Spectrometry (GC-MS) was performed on an Agilent 5977A mass spectrometer with an Agilent 7890A gas chromatography inlet. Liquid Chromatography Mass Spectrometry (LC-MS) was used to obtain low-resolution mass spectra (LRMS) and was performed on an Agilent 6120 mass spectrometer with an Agilent 1220 Infinity liquid chromatography inlet. Purity of all tested compounds was determined by HPLC analysis, using the methods given below (as indicated for each compound). 
Endo 5-hexyl-4-phenyl-3a-(1-phenylvinyl)-1,2,3,3a,6,6a-hexahydropentalen-1-amine (1N):
Under nitrogen, a solution of S3N (54 mg, 0.13 mmol, 1.0 equiv) in anhydrous Et2O was cooled to 0 °C and treated dropwise with LiAlH4 (4.0M in Et2O, 10.0 equiv). The reaction was stirred at ambient temperature until the reaction was complete by TLC (ca. 1 h). The reaction was cooled to 0 °C, diluted with anhydrous Et2O, and slowly treated with water (1mL/g LiAlH4). Excess 4 M NaOH was added slowly and the solution was extracted with EtOAc three times. The combined organic layers were washed with Rochelle's salt and brine, dried over MgSO4, and concentrated.
The crude oil was purified by silica gel chromatography in 50% EtOAc/Hexanes eluent (1% triethylamine) to afford the title compounds as a colorless oil. 1N: 47.9 mg, 95% yield. Purity was established by Method C: tr = 0.302 min, 98.6%. Protein purification. Purification of human LRH-1 ligand binding domain (residues 300-537) in a pMCSG7 expression vector was performed as described 13 . Briefly, protein was expressed in BL21 PLysS E. coli, using 1 mM IPTG for 4 hours (30°C) to induce expression. Protein was purified by nickel affinity chromatography. For DSF assays, protein eluted from the nickel column was exchanged with DLPC (5-fold molar excess overnight at 4 °C), followed by repurification by size exclusion to remove displaced lipids. The assay buffer was 20 mM Tris-HCl, pH 7.5, 150 mM sodium chloride, and 5% glycerol. Cleaved LRH-1 was then incubated with ligands overnight at 4 °C prior to repurification by size exclusion, using the same assay buffer as for DSF. Protein used for crystallography was prepared as for coregulator recruitment, except that it was sized into a buffer of 100 mM ammonium acetate (pH 7.5), 150 mM sodium chloride, 1 mM DTT, 1 mM EDTA, and 2 mM CHAPS.
N-((endo)-5-hexyl-4-phenyl-3a-(1-phenylvinyl)-1,2,3,3a,6,6a-hexahydropentalen-1-yl)acetamide

Differential scanning fluorimetry (DSF)
. DSF assays were conducted on a StepOne Plus thermocycler as previously described 13, 15 . Briefly, aliquots of purified LRH-1 LBD protein (0.2 mg/ ml) were incubated with saturating concentrations of ligand overnight at 4 °C. Protein-ligand complexes were heated in the presence of SYPRO orange dye at a rate of 0.5 degree/ minute.
Complexes were excited at 488 nm, and fluorescence emissions at each degree Celsius were measured using the ROX filter (~600 nm). Tm values were calculated using the Bolzmann equation in GraphPad Prism, v7.
Crystallography. Compounds 5N, 6N , or 2N were incubated with purified LRH-1 LBD (His tag removed) at 5-fold molar excess overnight at 4°C. The complexes were re-purified by size exclusion chromatography into the crystallization buffer (see above). Protein was concentrated to 5-6 mg/ ml and combined with a peptide from human Tif2 NR box 3 (H3N-KENALLRYLLDKDDT-CO2) at four-fold molar excess. Crystals were generated by hanging drop vapor diffusion at 18 °C, using a crystallant of 0.05 M sodium acetate (pH 4.6), 5-11% PEG 4000, and 0-10% glycerol. Crystals of 2N with LRH-1 were generated by microseeding, using RJW100-LRH-1 crystals as the seed stocks (crystals used for seeding were grown as described) 13 .
Structure Determination. Crystals were flash-frozen in liquid nitrogen, using a cryoprotectant of crystallant plus 30% glycerol. Diffraction data were collected remotely from Argonne National Laboratory, Southeast Regional Collaborative Access Team, Beamline 22ID. Data were processed and scaled using HKL2000
44
. Structures were phased by molecular replacement using Phenix 45 , with PBD 5L11 used as the search model. The structure was refined using phenix.refine 45 EC50 values were calculated using three-parameter curve-fitting (GraphPad Prism, v.7). Assays were conducted in triplicate with at least two independent biological replicates. Experiments involving SF-1 activation were conducted in an identical manner, except full-length human SF-1 (in a pcDNA3.1+ vector) was overexpressed instead of LRH-1. Significance of differences in luminescence signal for LRH-1 versus SF-1 promoted by particular agonists was determined using two-way ANOVA followed by Sidak's multiple comparisons test.
Calculation of Relative Efficacy (RE).
This value was calculated from curve-fitting to data from luciferase reporter assays. To compare the maximum activities of the new compounds to RJW100, we used the formula (Maxcpd -Mincpd) / (MaxRJW100 -MinRJW100), where "Max" and "Min" denote the dose response curve maximum and minimum, respectively. A RE of 0 indicates a completely inactive compound, a value of 1 indicates equal activity to RJW100, and values above 1 indicate greater activity.
Mutagenesis.
Mutations were introduced to LRH-1 in the pCI vector using the Quikchange
Lightning site-directed mutagenesis kit (Ambion). Constructs were sequenced prior to use in reporter gene assays as described above.
Model Construction for Molecular Dynamics Simulations. Four LRH-1 LBD complexes were prepared for molecular dynamics simulations. 1) LRH-1-Tif2-RJW100 (PDB 5L11), 2) LRH-1-Tif2-5N. 3LRH-1-Tif2-2N, LRH-1-Tif2-6N. For consistency, all structures contained LRH-1 residues 300-540. Missing residues (i.e., that could not be modeled in the structures) were added to the models used in the simulations.
Molecular Dynamics Simulations.
The complexes were solvated in an octahedral box of TIP3P
water with a 10-Å buffer around the protein complex. Na + and Cl -ions were added to neutralize the protein and achieve physiological buffer conditions. All systems were set up using the xleap tool in AmberTools17 48 with the ff14SB forcefield 49 . Parameters for the agonist ligands 6N, 2N and 5N
were obtained using Antechamber 50 also in AmberTools17. All minimizations and simulations were performed with Amber16
48
. Systems were minimized with 5000 steps of steepest decent followed by 5000 steps of conjugate gradient minimization with 500-kcal/mol•Å 2 restraints on all solute atoms. Restraints were removed excluding the atoms in both the ligand and the Tif2 peptide, and the previous minimization was repeated. This minimization was repeated with restraints lowered to 100-kcal/mol•Å
2
. Finally, all restraints were removed for a last minimization step. The systems were heated from 0 to 300 K using a 100-ps run with constant volume periodic boundaries and 5-kcal/mol•Å 2 restraints on all protein and ligand atoms. MD equilibration was performed for 12 ns with 10-kcal/mol•Å 2 restraints on Tif2 peptide and ligand atoms using the NPT ensemble.
Restraints were reduced to 1 kcal/mol•Å 2 for an additional 10 ns of MD equilibration. Then, restraints were removed, and 1000-ns production simulations were performed for each system in the NPT ensemble. A 2-fs time step was used with all bonds between heavy atoms and hydrogens fixed with the SHAKE algorithm
51
. A cutoff distance of 10 Å was used to evaluate long-range electrostatics with particle mesh Ewald and for van der Waals forces. Fifty thousand evenly spaced frames were taken from each simulation for analysis, using the CPPTRAJ module 52 of AmberTools.
The NetworkView plugin 20 in VMD 53 and the Carma program 54 were used to produce dynamic networks for each system. In brief, networks are constructed by defining all protein C-α atoms as nodes, using Cartesian covariance to measure communication within the network. Pairs of nodes that reside within a 4.5-Å cutoff for 75% of the simulation are connected via an edge. Edge weights are inversely proportional to the covariance between the nodes. Networks were constructed using 500 ns of the MDS trajectories, to enable direct comparison with our previous LRH-1-RJW MDS 15 .
Suboptimal paths between the AF-B and Tif2 peptide were identified using the Floyd-Warshall algorithm 55 . Suboptimal path analyses were performed using Carma and the subopt program in NetworkView. Cross-correlation matrices for C-α atoms in each system were computed with Carma.
Coregulator Recruitment Assays. Synthetic agonists were titrated in the presence of purified Significance of differences in Tif2 association at each dose was determined using two-way ANOVA followed by Tukey's multiple comparisons test.
Hydrogen-deuterium exchange mass spectrometry. Following cleavage of the His tag from purified LRH-1 LBD with TEV protease as described above, the protein was further purified by size exclusion chromatography into a buffer of phosphate buffered saline (pH 7.5) plus 5%
glycerol. Protein purity exceeded 98% by Coomassie staining. Protein-ligand complexes were prepared by adding each ligand at 5-fold molar excess to 2 mg/ml protein and incubating overnight at 4 °C. Complexes were centrifuged to remove any aggregates prior to analysis by HDX-MS. 
HDX-MS was conducted using
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